William C. Gruber

42.8k citations

232 papers · 12.4k indexed · 2 hit papers · h-index 58

Physical Therapy, Sports Therapy and Rehabilitation top 0.2%
Microbiology top 0.1%
- Bacterial Infections and Vaccines 67
Epidemiology top 0.05%
- Respiratory viral infections research 147
- Pneumonia and Respiratory Infections 146
- Influenza Virus Research Studies 54
- Pneumocystis jirovecii pneumonia detection and treatment 45
Infectious Diseases top 0.5%
- Viral gastroenteritis research and epidemiology 17
Health top 1%
Immunology
- Immunodeficiency and Autoimmune Disorders 14
Pulmonary and Respiratory Medicine
- Neonatal Respiratory Health Research 12

Co-authors: Anne Shumway‐Cook Margaret Baldwin Daniel A. Scott Nayak L. Polissar Robert B. Belshe Emilio A. Emini Kathrin U. Jansen Alejandra Gurtman
Cited by: Physical Therapy, Sports Therapy and Rehabilitation Microbiology Epidemiology
Journals: New England Journal of Medicine (2 papers)Nature Communications (1 paper)Blood (1 paper)
Partner nations: United States Germany United Kingdom

In The Last Decade

William C. Gruber

222 papers receiving 11.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by William C. Gruber

Since Specialization

Citations

This map shows the geographic impact of William C. Gruber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Gruber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Gruber more than expected).

Fields of papers citing papers by William C. Gruber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Gruber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Gruber. The network helps show where William C. Gruber may publish in the future.

Co-authorship network

The 25 scholars most cited alongside William C. Gruber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William C. Gruber Line = papers co-authored together William C. Gruber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine Vaccine ·Federico Martinón‐Torres,Silvina Natalini Martinez,Mary Kline,Jelena Drozd,James Trammel,Yahong Peng,Peter C. Giardina,William C. Gruber,Wendy Watson,Kara Bickham,Noor Tamimi	2025	0
2	Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa Open Forum Infectious Diseases ·Shabir A. Madhi,Eric A. F. Simões,Nicola P. Klein,Agnieszka Zareba,Philip R. Dormitzer,Daniel A. Scott,Alejandra Gurtman,William C. Gruber,Kathrin U. Jansen,David Cooper,Bing Cai,Beate Schmöele-Thoma,Kena A. Swanson	2025	0
3	A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age Infectious Diseases and Therapy ·Susanna Koski,Federico Martinón‐Torres,Mika Rämet,Lefteris Zolotas,Ryan Newton,Roger Maansson,Mark Cutler,Paula Peyrani,Jamie Findlow,Paul Balmer,Luis Jódar,William C. Gruber,Annaliesa S. Anderson,Johannes Beeslaar	2025	0
4	Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose Vaccine ·James T. Peterson,Daniel Dražan,Beth Moughan,Jason D. Maguire,Lefteris Zolotas,Roger Maansson,Robert O’Neill,Paula Peyrani,Luis Jódar,William C. Gruber,Annaliesa S. Anderson,Johannes Beeslaar	2024	0
5	A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants International Journal of Infectious Diseases ·Yasunori Ishihara,Mitsuru Fukazawa,Shinya Enomoto,Richard de Solom,Masako Yamaji,Mary Kline,Masakazu Aizawa,Yahong Peng,Osamu Kogawara,Peter C. Giardina,Noor Tamimi,William C. Gruber,Wendy Watson	2024	2
6	A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization Vaccines ·Bing Cai,Yili Chen,Yasmeen Agosti,Beate Schmöele-Thoma,Kenneth Koury,Kathrin U. Jansen,William C. Gruber,Philip R. Dormitzer,Kena A. Swanson	2024	0
7	A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan Vaccine ·Miwa Haranaka,Joon Young Song,Kuo‐Chin Huang,Richard de Solom,Masako Yamaji,Kathleen McElwee,Mary Kline,Masakazu Aizawa,Yahong Peng,Ingrid L. Scully,Osamu Kogawara,William C. Gruber,Daniel A. Scott,Wendy Watson	2024	6
8	Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine The Journal of Infectious Diseases ·James T. Peterson,Agnieszka Zareba,David Fitzpatrick,Brandon Essink,Daniel A. Scott,Kena A. Swanson,Dhawal Chelani,David Radley,David Cooper,Kathrin U. Jansen,Philip R. Dormitzer,William C. Gruber,Alejandra Gurtman	2021	31
9	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age Human Vaccines & Immunotherapeutics ·Brandon Essink,James T. Peterson,Kari Yacisin,Himal Lal,Sarah Mirza,Xia Xu,Ingrid L. Scully,Daniel A. Scott,William C. Gruber,Kathrin U. Jansen,Wendy Watson	2021	2
10	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age Vaccine ·Nicola P. Klein,Paula Peyrani,Kari Yacisin,Nicole Caldwell,Xia Xu,Ingrid L. Scully,Daniel A. Scott,Kathrin U. Jansen,William C. Gruber,Wendy Watson	2021	53
11	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States Human Vaccines & Immunotherapeutics ·David Fitzpatrick,Mariano Young,Daniel A. Scott,Ingrid L. Scully,Gary Baugher,Yahong Peng,Kathrin U. Jansen,William C. Gruber,Wendy Watson	2021	9
12	Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults Human Vaccines & Immunotherapeutics ·Beate Schmöele-Thoma,Martin van Cleeff,Richard N. Greenberg,Alejandra Gurtman,Thomas R. Jones,Vani Sundaraiyer,William C. Gruber,Daniel A. Scott	2019	6
13	Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial Human Vaccines & Immunotherapeutics ·Allison Thompson,Nicola P. Klein,H. Jackson Downey,Scott D. Patterson,Vani Sundaraiyer,Wendy Watson,Keri Clarke,Kathrin U. Jansen,Shite Sebastian,William C. Gruber,Daniel A. Scott,Beate Schmöele-Thoma	2018	16
14	Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations Human Vaccines & Immunotherapeutics ·Christine Juergens,James Trammel,Yasuko Shoji,Scott D. Patterson,Wendy Watson,Chris Webber,William C. Gruber,Daniel A. Scott,Beate Schmöele-Thoma	2018	4
15	Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial Human Vaccines & Immunotherapeutics ·Bhagirath Solanki,Christine Juergens,Manojkumar B. Chopada,Pravin Dinkar Supe,Vani Sundaraiyer,Natacha Le Dren-Narayanin,Mark Cutler,William C. Gruber,Daniel A. Scott,Beate Schmöele-Thoma	2017	12
16	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. PubMed ·Maricruz Gutiérrez Brito,Allison Thompson,Douglas Girgenti,Peter C. Giardina,Denise A. Sarkozy,William C. Gruber,Emilio A. Emini,Daniel A. Scott	2013	4
17	Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India The Pediatric Infectious Disease Journal ·Y. K. Amdekar,Sanjay Lalwani,Ashish Bavdekar,Sundaram Balasubramanian,Jugesh Chhatwal,Swarna Rekha Bhat,Valsan Philip Verghese,S. Tansey,Durga Gadgil,Qin Jiang,Michael W. Pride,Emilio A. Emini,William C. Gruber,Daniel A. Scott	2012	16
18	Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK ePrints Soton (University of Southampton) ·J.Y. Hughes,Snape,Chaam L. Klinger,Elvis D. Daniels,H. Laytone,Llinos Rollinson,S. Pestridge,E. Dymond,Eva Galiza,Daniel A. Scott,Scott D. Patterson,William C. Gruber,L Mei Yu,Saul N. Faust,Adam Finn,Paul T. Heath,Andrew J. Pollard	2009	9
19	Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions The Pediatric Infectious Disease Journal ·Richard Malley,Louis Vernacchio,John P. DeVincenzo,Octavio Ramilo,Penelope H. Dennehy,H. Cody Meissner,William C. Gruber,Hasan S. Jafri,Pablo J. Sánchez,Kristin MacDonald,John B Montana,Claudette M. Thompson,Donna M. Ambrosino	2000	21
20	Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections Clinical Pharmacology & Therapeutics ·John M. Trang,Lauren B. Kidd,William C. Gruber,Gregory A. Storch,Gail J. Demmler,Richard A. Jacobs,Wayne M. Dankner,Stuart E. Starr,Robert F. Pass,Sergio Stagno,Charles A. Alford,Seng‐Jaw Soong,Richard J. Whitley,Jean‐Pierre Sommadossi,Niaid Collaborative Antiviral Study Group	1993	70

About William C. Gruber

William C. Gruber is a scholar working on Microbiology, Epidemiology and Infectious Diseases, having authored 232 papers that have together received 12.4k indexed citations. Recurring topics across this work include Respiratory viral infections research (147 papers), Pneumonia and Respiratory Infections (146 papers), Bacterial Infections and Vaccines (67 papers), Influenza Virus Research Studies (54 papers), Pneumocystis jirovecii pneumonia detection and treatment (45 papers), Viral gastroenteritis research and epidemiology (17 papers), Immunodeficiency and Autoimmune Disorders (14 papers) and Neonatal Respiratory Health Research (12 papers). The work is most often cited by research in Physical Therapy, Sports Therapy and Rehabilitation (1.3k citations), Microbiology (1.7k citations) and Epidemiology (9.3k citations). William C. Gruber has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Anne Shumway‐Cook, Margaret Baldwin, Daniel A. Scott, Nayak L. Polissar, Robert B. Belshe, Emilio A. Emini, Kathrin U. Jansen, Alejandra Gurtman, Pedro A. Piedra and Beate Schmöele-Thoma. Their work appears in journals such as New England Journal of Medicine, Nature Communications and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact